Lonza, a pharmaceutical and biotech processing partner, has added clinical bottling and labelling capabilities to its small molecule manufacturing site in Oregon, US.
This strategic move builds on Lonza's prior investment into a dedicated early-phase clinical manufacturing facility.
The Oregon site now includes novel bottling equipment for filling both tablets and powder-filled capsules.
The new equipment, according to the company, can detect tablet and capsule defects, while also cleaning, filling, capping, sealing and labelling bottles intended for use in early-phase clinical trials.
Lonza has created this solution to accelerate the product delivery process to clinical trial centres.
The Senior Director of Product Development for Small Molecules at Lonza, Matthew Ferguson, commented: “Lonza’s drug product formulation and development services, offered from our site in Bend, support clinical and commercial development and manufacturing. The new bottling equipment for filling tablets and powder-filled capsules further enhances our ability to support customers looking to accelerate their candidate pathway through phase I and II clinical trials and beyond.”
Lonza’s facility in Bend serves as the company’s Centre of Excellence for bioavailability enhancement and inhaled delivery.
For more than 45 years, the Bend team has been at the forefront of addressing solubility challenges and modulating pharmacokinetics to meet target product profiles for Lonza — with the site currently supporting more than 80 programmes.
[Image credit: Lonza]
